more

Summit Therapeutics (SMMT)

(Delayed Data from NSDQ)

$3.86 USD

+0.31 (8.73%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.86 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

Industry Rank:

Top 35% (89 out of 252)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?

by Zacks Equity Research Published on May 19,2021

Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

SMMTPositive Net Change

Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher

by Zacks Equity Research Published on December 16,2020

Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

SMMTPositive Net Change

medical

New Strong Sell Stocks for October 30th

by Zacks Equity Research Published on October 30,2020

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research Published on June 02,2020

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.

SMMTPositive Net Change

Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on June 01,2020

Is (SMMT) Outperforming Other Medical Stocks This Year?

SMMTPositive Net Change

Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research Published on May 27,2020

Summit Therapeutics PLC (SMMT) closed at $4.20 in the latest trading session, marking a +1.94% move from the prior day.

SMMTPositive Net Change

Summit Therapeutics PLC (SMMT) Stock Moves -0.43%: What You Should Know

by Zacks Equity Research Published on May 19,2020

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.

SMMTPositive Net Change

Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?

by Zacks Equity Research Published on May 18,2020

Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on May 13,2020

On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.

medical

Is Summit Therapeutics (SMMT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on May 13,2020

Is (SMMT) Outperforming Other Medical Stocks This Year?

SMMTPositive Net Change

Summit Therapeutics PLC (SMMT) Gains As Market Dips: What You Should Know

by Zacks Equity Research Published on May 06,2020

Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.11, moving +0.33% from the previous trading session.

SMMTPositive Net Change

Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on April 27,2020

Is (SMMT) Outperforming Other Medical Stocks This Year?

SMMTPositive Net Change

Summit Therapeutics PLC (SMMT) Gains But Lags Market: What You Should Know

by Zacks Equity Research Published on April 24,2020

Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.68, moving +0.55% from the previous trading session.

SMMTPositive Net Change

Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.9%

by Zacks Equity Research Published on April 17,2020

Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

medical

Here's Why Momentum Investors Will Love Summit Therapeutics PLC (SMMT)

by Zacks Equity Research Published on April 16,2020

Does Summit Therapeutics PLC (SMMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

SMMTPositive Net Change

Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on April 09,2020

Is (SMMT) Outperforming Other Medical Stocks This Year?

SMMTPositive Net Change

The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals

by Zacks Equity Research Published on April 08,2020

The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals

medical

5 Stocks Up on Signs of Slowdown in Coronavirus Cases

by Zacks Equity Research Published on April 07,2020

Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.